glp-1 agonists list Receptor America's Poison Centers - GLP-1

Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly

The second is to request additional information, such as lab work, before making a final decision

The development of GLP-1 receptor agonists Native GLP-1 is unsuitable itself as a therapeutic agent because of its short half-life in vivo

One or Two

Ozempic falls into a group of drugs known as GLP-1 receptor agonists (GLP-1 RAs)

Treatment should be discontinued after 12 weeks on the maintenance dose if patients have not lost at least 5% of their initial body weight